title: Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.
abstract: We assessed the pharmacokinetics and interactions of steady-state micafungin (Mycamine) or placebo with steady-state voriconazole in 35 volunteers. The 90% confidence intervals around the least-squares mean ratios for micafungin pharmacokinetic parameters and placebo-corrected voriconazole pharmacokinetic parameters were within the 80%-to-125% limits, indicating an absence of drug interaction.
authors.affiliation: Astellas Pharma US, Inc., 3 Parkway North, Deerfield, IL 60015-2548, USA. jim.keirns@us.astellas.com
authors.forename: J
authors.initials: J
authors.lastname: Keirns
authors.forename: T
authors.initials: T
authors.lastname: Sawamoto
authors.forename: M
authors.initials: M
authors.lastname: Holum
authors.forename: D
authors.initials: D
authors.lastname: Buell
authors.forename: W
authors.initials: W
authors.lastname: Wisemandle
authors.forename: A
authors.initials: A
authors.lastname: Alak
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D054714:Echinocandins; D005260:Female; D006801:Humans; D055666:Lipopeptides; D008074:Lipoproteins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D000077551:Micafungin; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011743:Pyrimidines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D014230:Triazoles / Q000008:administration & dosage / Q000493:pharmacokinetics*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D010456:Peptides, Cyclic; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole; D000077551:Micafungin